Danish Mazhar

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Renato D. Lópes, Celestia S. Higano, Susan F. Slovin et al. · Circulation · 2021 · 143 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +13

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen et al. · JAMA Oncology · 2022 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Johnathan Joffe, Fay Cafferty, Laura Murphy et al. · Journal of Clinical Oncology · 2022 · 59 citations · Full text

Medicine, Oncology, Radiology +17